Repeated Infusions of Levosimendan: Well Tolerated and Improves Functional Capacity in Decompensated Heart Failure - A Single-Centre Experience

Heart Lung and Circulation

Volumn 17, Issue 3, 2008, Pages 206-210

  Parle, N M ^a   Thomas, M D ^a   Dembo, L ^a   Best, M ^a   Driscoll, G O ' ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

BNP; Cardiomyopathy; Heart failure; Levosimendan; NYHA class; Repeated doses

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; LEVOSIMENDAN; NORADRENALIN; SPIRONOLACTONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL STATUS; HEART ASSIST DEVICE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART TRANSPLANTATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; LEG CRAMP; LOADING DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; NAUSEA; NON SUSTAINED VENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; REPEATED DRUG DOSE; TREATMENT OUTCOME;

ADULT; AGED; AMBULATORY CARE; CARDIOTONIC AGENTS; FEMALE; HEART FAILURE; HUMANS; HYDRAZONES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; PYRIDAZINES;

EID: 43049179359     PISSN: 14439506     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hlc.2007.10.014     Document Type: Article

References (18)

1. Thackray S., Easthaugh J., Freemantle N., and Cleland J.G. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail 4 (2002) 515-529
2. O'Connor C.M., Gattis W.A., Uretsky B.F., Adams Jr. K.F., McNulty S.E., Grossman S.H., McKenna W.J., Zannad F., Swedberg K., Gheorghiade M., and Califf R.M. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 138 (1999) 78-86
3. Felker G.M., Benza R.L., Chandler A.B., Leimberger J.D., Cuffe M.S., Califf R.M., Gheorghiade M., and O'Connor C.M. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 41 (2003) 997-1003
4. Monrad E.S., Baim D.S., Smith H.S., and Lanoue A.S. Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. Circulation 73 3 Pt 2 (1986) III168-III174
5. Papp Z., Csapo K., Pollesello P., Haikala H., and Edes I. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovasc Drug Rev 23 (2005) 71-98
6. Antila S., Sundberg S., and Lehtonen L.A. Clinical pharmacology of levosimendan. Clin Pharmacokinet 46 (2007) 535-552
7. Lilleberg J., Laine M., Palkama T., Kivikko M., Pohjanjousi P., and Kupari M. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail 9 (2007) 75-82
8. Follath F., Cleland J.G., Just H., Papp J.G., Scholz H., Peuhkurinen K., Harjola V.P., Mitrovic V., Abdalla M., Sandell E.P., and Lehtonen L. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360 (2002) 196-202
9. Moiseyev V.S., Poder P., Andrejevs N., Ruda M.Y., Golikov A.P., Lazebnik L.B., Kobalava Z.D., Lehtonen L.A., Laine T., Nieminen M.S., and Lie K.I. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 23 (2002) 1422-1432
10. Cleland J.G., Freemantle N., Coletta A.P., and Clark A.L. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 8 (2006) 105-110
11. Mebazaa A., Nieminen M.S., Packer M., Cohen-Solal A., Kleber F.X., Pocock S.J., Thakkar R., Padley R.J., Poder P., and Kivikko M. Levosimendan vs. dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 297 (2007) 1883-1891
12. Nanas J.N., Papazoglou P., Tsagalou E.P., Ntalianis A., Tsolakis E., Terrovitis J.V., Kanakakis J., Nanas S.N., and Alexopoulos G.P. Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone. Am J Cardiol 95 (2005) 768-771
13. Parissis J.T., Adamopoulos S., Farmakis D., Filippatos G., Paraskevaidis I., Panou F., Iliodromitis E., and Kremastinos D.T. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart 92 (2006) 1768-1772
14. Anand I.S., Fisher L.D., Chiang Y.T., Latini R., Masson S., Maggioni A.P., Glazer R.D., Tognoni G., and Cohn J.N. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 (2003) 1278-1283
15. Kyrzopoulos S., Adamopoulos S., Parissis J.T., Rassias J., Kostakis G., Iliodromitis E., Degiannis D., and Kremastinos D.T. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients. Int J Cardiol 99 (2005) 409-413
16. Parissis J.T., Panou F., Farmakis D., Adamopoulos S., Filippatos G., Paraskevaidis I., Venetsanou K., Lekakis J., and Kremastinos D.T. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 96 (2005) 423-426
17. McLean A.S., Huang S.J., Nalos M., and Ting I. Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide. J Cardiovasc Pharmacol 46 (2005) 830-835
18. Lilleberg J., Ylonen V., Lehtonen L., and Toivonen L. The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies. Scand Cardiovasc J 38 (2004) 80-84